Participated · Equity · Apr 2021

Medable offers a software-as-a-service platform that connects patients, trial sites and clinical trial teams to streamline trial design, recruitment, retention and data quality. Its technology is used in roughly 150 clinical trials across 5,000 clinical sites in 60 countries and has reached tens of thousands of patients. The company reports rapid growth, having grown 300% in the past year and over 800% in the last 18 months. Medable aims to cut trial costs roughly in half and double speed to market for new drugs. The new capital is intended to scale the technology globally and fund product development, its partner ecosystem, and customer and patient success. The firm is pursuing more localized trial execution, including work done at local pharmacies or clinics, to broaden access to experimental therapies. Medable offers a flexible, modular software platform that supports decentralized and digital clinical trials, including recruitment, remote screening, electronic consent, eCOA, eSource, telemedicine, and connected devices. Its platform has been used across therapeutic areas in more than 60 countries and in over 40 languages. In 2020 the company reported record growth—revenues grew by more than 400%—and customers achieved 3X faster enrollment and over 90% retention; Medable also launched five new products and onboarded more than 50 new clients that year. Medable will use the new funding to accelerate broad adoption of digital trials at global scale and to advance initiatives around ubiquitous research access, patient data fluidity, and intelligent monitoring of patients and trial data. The company has expanded its leadership team (hiring a CSO, CPO, CDO, and COO), grown its Patient Advisory Council and Patient Champion Network, and formed a partnership with Seqster to integrate real-world data streams. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Medable provides a flexible, modular software platform that enables clinical leaders to shift from clinic-centric to patient-centric research strategies, offering recruitment, remote screening, electronic consent, clinical outcomes assessment (eCOA), eSource, telemedicine, and connected-device integration. The platform delivers a unified experience for patients and clinicians to conduct complex protocols remotely and minimize in-person site visits. During the COVID-19 pandemic Medable facilitated continuation of existing research and accelerated development of vaccines and therapeutics by enabling remote care. The company reported revenue growth of more than 500% in 2020 and its platform has been used in registrational clinical trials across more than 60 countries and in over 40 languages. Recent product launches include TeleVisit, TeleConsent, and TeleCOA mobile applications, and Medable has announced partnerships with Datavant, MRN, and AliveCor to expand data integration and home-visit capabilities. Medable has also established a Patient Advisory Council and a multi-company research framework to accelerate COVID-19 diagnostics and treatments. The company says the new funding will be used to accelerate the life sciences industry’s shift to digital and decentralized trials and to pursue new technologies that improve patient access, experience, and outcomes. Medable operates a modular digital platform-as-a-service that connects clinical trial participants, sites, partners and analytics to enable more patient-centric and informed clinical research. The platform streamlines trial design, recruitment, retention and data quality and is used by leading biopharma sponsors and clinical research organizations. Medable's technology has been deployed in more than 30 countries and supports 26 languages. The company has formed partnerships with PPD, MRN and AliveCor and has introduced global telemedicine and in-home care capabilities to support COVID-19 research. Medable aims to reduce clinical trial timelines by 50 percent and plans to use recent funding to extend product development, partnerships and market adoption. The company has raised more than $45 million in total capital and is headquartered in Palo Alto, California.

Led · Equity · Aug 2020

Science 37 operates a decentralized clinical trial platform that coordinates telemedicine investigators and home‑health nurses to run interventional trials outside traditional clinical sites. Led by CEO David Coman, the company enables patients to participate in trials from anywhere without traveling to study sites. It closed a $40M funding round to support growth, expand its technology platform, and accelerate global expansion. The company says the new capital will strengthen its ability to help sponsors execute decentralized trials. Science 37 leverages an expansive network of clinical staff integrated with its platform to deliver decentralized trial services. The company is based in Los Angeles, CA. Science37 provides a proprietary software platform, the Network Oriented Research Assistant, that lets qualified patients access and participate in clinical trials from home using mobile devices and assigned mobile nurses. The company offers patients free tools and remote monitoring (including iPhones provided for some studies) to broaden access for those in rural areas or with scheduling constraints. Science37 is focused on studies in dermatology, oncology and headaches and also conducts trials for other research organizations. Its model has reduced recruitment time by nearly 50% in some cases, and the company sees an opportunity to increase minority representation in trials (current minority participation is cited at about 5%, with cancer trials sometimes below 2%). Planned uses of new funding include further development of the platform, expansion into new therapeutic areas, and recruiting talent from technology and clinical-trial industries to reach more diverse demographics. Science 37 is a Los Angeles-based mobile technology and clinical trial startup founded in 2014 that develops a patient-centered virtual clinical trial model. Its proprietary NORA (Network Oriented Research Assistant) platform is a cloud-based, mobile research platform that enables recruitment, electronic informed consent, patient counseling, endpoint measurement, and remote monitoring. The company replaces physical trial sites with a single "metasite™" to bring trials to patients' homes, enabling telemedicine and home visits and improving access for patients outside local site areas and those with rare diseases. Science 37 aims to reduce trial time and cost, improve recruitment and retention, and address bottlenecks in site identification and enrollment. The Series B investment will help expand operations, support further development of NORA, and enable expansion into new therapeutic areas. As part of the strategic investment, Sanofi’s international clinical trial teams will provide technical and strategic guidance. Science 37 is a Los Angeles-based technology-enabled clinical research company led by co-founder and CEO Noah Craft, MD, PhD. It is advancing a metasite operating model that delivers end-to-end clinical trial services under a single contract by leveraging partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups and other technology companies. Its technology platform, the Network Oriented Research Assistant (NORA), utilizes telemedicine and coordinates mobile workforces to overcome geographic barriers and expand access to trials, including underserved and minority populations. The company completed a $6.5M Series A financing and intends to use the funds to accelerate development and rollout of the metasite operating model. Science 37 aims to solve inefficiencies in conducting clinical trials by combining its platform with on-the-ground partners and technology integrations.

Participated · Series C · Apr 2010

Liquidia Technologies commercializes PRINT®, a proprietary platform that precisely controls particle size, shape, and chemistry to improve delivery of biologics and small molecules for vaccine and therapeutic applications. The company licenses its PRINT technology and GMP manufacturing capabilities to collaborators and advances its own product candidates. Liquidia has initiated the first clinical trial of its lead seasonal flu candidate, LIQ001, and has a collaborative agreement with the PATH Malaria Vaccine Initiative. The company says PRINT enables scalable, consistent manufacturing and the ability to tune particle parameters to create cost-effective, potent vaccines for various disease targets. Liquidia aims to support global vaccine demand by producing highly efficacious therapies at appropriate quantities and costs. The company is located in Research Triangle Park, North Carolina, and was founded on discoveries by Professor Joseph DeSimone and colleagues at the University of North Carolina, Chapel Hill. Liquidia Technologies is a biopharmaceutical company developing particle-based vaccines and therapeutics. The company is based in Research Triangle Park, North Carolina. Its pipeline is led by a lead vaccine candidate that the company plans to advance through initial clinical studies. Liquidia focuses on particle-based solutions for novel vaccines and therapeutics. The company expanded its Series C financing to support these development efforts. Proceeds from the financing will be used to accelerate the lead vaccine candidate and to expand development of its particle-based technology. Liquidia Technologies is a nanotechnology company that develops a proprietary PRINT manufacturing platform for producing precisely engineered particles. The PRINT process enables efficient delivery of vaccine and therapeutic drug products through controlled particle engineering. The company will receive approximately $3M in funding from the U.S. Commerce Department’s National Institute of Standards and Technology to further develop and scale up the platform. Those scale-up capabilities are intended to support advancement of a platform of products, including Liquidia’s initial vaccine candidate. The initial vaccine product is expected to enter clinical trials next year. Liquidia is based in Research Triangle Park, North Carolina.